Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics
If you're considering investing in the gene editing sector, it's worth taking some time to look through all the main players in this small but promising biotech market. At the moment, there are just a few noteworthy companies in this space, all of them still at early clinical stages despite commanding market valuations well into the billions of dollars.
CRISPR Therapeutics (NASDAQ: CRSP) is likely the first gene editing stock to come to mind, and it's considered by many to be the leading company in the market, if only by market cap. However, smaller companies, like Sangamo Therapeutics (NASDAQ: SGMO), also have plenty of promise.
If you're wondering which of these two stocks is the better buy, then read below to find out all the details.
Source Fool.com
